blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1827468

EP1827468 - Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease [Right-click to bookmark this link]
Former [2007/36]LEUPROLIDE ACETATE AND ACETYLCHOLINESTERASE INHIBITORS OR NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
[2012/14]
StatusNo opposition filed within time limit
Status updated on  28.06.2013
Database last updated on 24.08.2024
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
Curaxis Pharmaceutical Corporation
1004 Chagford Way
Raleigh, NC 27614 / US
[2012/24]
Former [2010/08]For all designated states
Voyager Pharmaceutical Corporation
12600 Deerfield Parkway Suite 100
Alpharetta, GA 30004 / US
Former [2007/36]For all designated states
Voyager Pharmaceutical Corporation
8540 Colonnade Center Drive, Suite 409
Raleigh, NC 27615 / US
Inventor(s)01 / GREGORY, Christopher, W.
102 Avella Court
Cary, NC 27519 / US
02 / SMITH, Patrick, S.
4800 Wynneford Way
Raleigh, NC 27614 / US
 [2007/36]
Representative(s)Harris, Jennifer Lucy, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[N/P]
Former [2011/37]Harris, Jennifer Lucy, et al
Kilburn & Strode LLP 20 Red Lion Street
London WC1R 4PJ / GB
Former [2007/36]Lee, Nicholas John, et al
Kilburn & Strode 20 Red Lion Street
London WC1R 4PJ / GB
Application number, filing date05771273.913.07.2005
[2007/36]
WO2005US24656
Priority number, dateUS20040638123P23.12.2004         Original published format: US 638123 P
[2007/36]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2006071274
Date:06.07.2006
Language:EN
[2006/27]
Type: A2 Application without search report 
No.:EP1827468
Date:05.09.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 06.07.2006 takes the place of the publication of the European patent application.
[2007/36]
Type: B1 Patent specification 
No.:EP1827468
Date:22.08.2012
Language:EN
[2012/34]
Search report(s)International search report - published on:US11.01.2007
(Supplementary) European search report - dispatched on:EP06.07.2009
ClassificationIPC:A61P25/28, A61K31/445, A61K31/55
[2012/14]
CPC:
A61K31/55 (EP,US); A61K31/445 (EP,US); A61K38/09 (EP,US);
A61K45/06 (EP,US); A61P25/28 (EP); A61P39/00 (EP);
A61P43/00 (EP); A61P5/06 (EP) (-)
C-Set:
A61K31/445, A61K2300/00 (US,EP);
A61K31/55, A61K2300/00 (US,EP);
A61K38/09, A61K2300/00 (EP,US)
Former IPC [2007/36]A61K38/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/36]
TitleGerman:Acetylcholinesterasehemmer und Leuprolidacetat zur Behandlung von Alzheimer-Krankheit[2012/14]
English:Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease[2012/14]
French:Inhibiteurs de l'acetylcholinesterase et acétate de leuprolide pour le traitement de la maladie d'Alzheimer[2012/16]
Former [2007/36]LEUPROLIDACETAT UND ACETYLCHOLINESTERASE-HEMMER ODER NMDA-REZEPTORANTAGONISTEN ZUR BEHANDLUNG VON ALZHEIMER-KRANKHEIT
Former [2007/36]LEUPROLIDE ACETATE AND ACETYLCHOLINESTERASE INHIBITORS OR NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
Former [2007/36]ACETATE DE LEUPROLIDE ET INHIBITEURS DE L'ACETYLCHOLINESTERASE OU ANTAGONISTES DES RECEPTEURS NMDA POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
Entry into regional phase04.07.2007National basic fee paid 
04.07.2007Search fee paid 
04.07.2007Designation fee(s) paid 
04.07.2007Examination fee paid 
Examination procedure18.07.2006Request for preliminary examination filed
International Preliminary Examining Authority: US
28.06.2007Amendment by applicant (claims and/or description)
04.07.2007Examination requested  [2007/36]
03.09.2009Despatch of a communication from the examining division (Time limit: M06)
15.03.2010Reply to a communication from the examining division
02.08.2011Despatch of a communication from the examining division (Time limit: M04)
01.11.2011Reply to a communication from the examining division
20.01.2012Despatch of a communication from the examining division (Time limit: M02)
31.01.2012Reply to a communication from the examining division
28.03.2012Communication of intention to grant the patent
26.06.2012Fee for grant paid
26.06.2012Fee for publishing/printing paid
Divisional application(s)EP11181112.1  / EP2425845
EP11181114.7  / EP2425846
EP11181115.4   Application deemed to be withdrawn  : 14.09.2011
EP11181117.0   Application deemed to be withdrawn  : 14.10.2011
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  03.09.2009
Opposition(s)23.05.2013No opposition filed within time limit [2013/31]
Fees paidRenewal fee
04.07.2007Renewal fee patent year 03
21.01.2009Renewal fee patent year 04
13.01.2010Renewal fee patent year 05
14.07.2010Renewal fee patent year 06
26.07.2011Renewal fee patent year 07
13.07.2012Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
31.07.200804   M06   Fee paid on   21.01.2009
31.07.200905   M06   Fee paid on   13.01.2010
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU13.07.2005
AT22.08.2012
BE22.08.2012
CY22.08.2012
CZ22.08.2012
DK22.08.2012
EE22.08.2012
FI22.08.2012
IT22.08.2012
LT22.08.2012
LV22.08.2012
MC22.08.2012
NL22.08.2012
PL22.08.2012
RO22.08.2012
SE22.08.2012
SI22.08.2012
SK22.08.2012
TR22.08.2012
BG22.11.2012
GR23.11.2012
ES03.12.2012
IS22.12.2012
PT24.12.2012
[2015/34]
Former [2015/32]AT22.08.2012
BE22.08.2012
CY22.08.2012
CZ22.08.2012
DK22.08.2012
EE22.08.2012
FI22.08.2012
IT22.08.2012
LT22.08.2012
LV22.08.2012
MC22.08.2012
NL22.08.2012
PL22.08.2012
RO22.08.2012
SE22.08.2012
SI22.08.2012
SK22.08.2012
TR22.08.2012
BG22.11.2012
GR23.11.2012
ES03.12.2012
IS22.12.2012
PT24.12.2012
Former [2014/14]AT22.08.2012
BE22.08.2012
CY22.08.2012
CZ22.08.2012
DK22.08.2012
EE22.08.2012
FI22.08.2012
IT22.08.2012
LT22.08.2012
LV22.08.2012
MC22.08.2012
NL22.08.2012
PL22.08.2012
RO22.08.2012
SE22.08.2012
SI22.08.2012
SK22.08.2012
BG22.11.2012
GR23.11.2012
ES03.12.2012
IS22.12.2012
PT24.12.2012
Former [2013/34]AT22.08.2012
BE22.08.2012
CY22.08.2012
CZ22.08.2012
DK22.08.2012
EE22.08.2012
FI22.08.2012
IT22.08.2012
LT22.08.2012
LV22.08.2012
NL22.08.2012
PL22.08.2012
RO22.08.2012
SE22.08.2012
SI22.08.2012
SK22.08.2012
BG22.11.2012
GR23.11.2012
ES03.12.2012
IS22.12.2012
PT24.12.2012
Former [2013/23]AT22.08.2012
BE22.08.2012
CY22.08.2012
CZ22.08.2012
DK22.08.2012
EE22.08.2012
FI22.08.2012
IT22.08.2012
LT22.08.2012
LV22.08.2012
NL22.08.2012
PL22.08.2012
RO22.08.2012
SE22.08.2012
SI22.08.2012
SK22.08.2012
GR23.11.2012
ES03.12.2012
IS22.12.2012
PT24.12.2012
Former [2013/22]AT22.08.2012
BE22.08.2012
CY22.08.2012
CZ22.08.2012
DK22.08.2012
EE22.08.2012
FI22.08.2012
LT22.08.2012
LV22.08.2012
NL22.08.2012
SE22.08.2012
SI22.08.2012
GR23.11.2012
ES03.12.2012
IS22.12.2012
PT24.12.2012
Former [2013/21]AT22.08.2012
BE22.08.2012
CY22.08.2012
DK22.08.2012
FI22.08.2012
LT22.08.2012
LV22.08.2012
NL22.08.2012
SE22.08.2012
SI22.08.2012
GR23.11.2012
IS22.12.2012
PT24.12.2012
Former [2013/15]AT22.08.2012
BE22.08.2012
CY22.08.2012
FI22.08.2012
LT22.08.2012
LV22.08.2012
NL22.08.2012
SE22.08.2012
SI22.08.2012
GR23.11.2012
IS22.12.2012
PT24.12.2012
Former [2013/13]AT22.08.2012
BE22.08.2012
CY22.08.2012
FI22.08.2012
LT22.08.2012
LV22.08.2012
SE22.08.2012
SI22.08.2012
GR23.11.2012
IS22.12.2012
PT24.12.2012
Former [2013/12]AT22.08.2012
BE22.08.2012
CY22.08.2012
FI22.08.2012
LT22.08.2012
LV22.08.2012
SE22.08.2012
SI22.08.2012
GR23.11.2012
IS22.12.2012
Former [2013/11]AT22.08.2012
CY22.08.2012
FI22.08.2012
LT22.08.2012
LV22.08.2012
SI22.08.2012
GR23.11.2012
IS22.12.2012
Former [2013/10]AT22.08.2012
CY22.08.2012
FI22.08.2012
LT22.08.2012
IS22.12.2012
Former [2013/09]AT22.08.2012
FI22.08.2012
LT22.08.2012
Former [2013/08]AT22.08.2012
LT22.08.2012
Former [2013/07]AT22.08.2012
Documents cited:Search[X]GB2352716  (LILLY CO ELI [US]) [X] 8,9 * page 2, line 25 - page 3, line 5 * * page 20, lines 10-18 * * claims 2,8 *;
 [DY]US6242421  (BOWEN RICHARD LLOYD [US]) [DY] 1-3,5-9 * column 4, lines 3-46 * * column 5, lines 5-19 * * column 7, lines 4-35 * * column 8, lines 15-50; claims 1-12 *;
 [A]US2002177556  (ENGEL JURGEN [DE], et al) [A] * the whole document *;
 [X]US6610706  (BUSH JULIE KAY [US], et al) [X] 8,9 * col 1 last 2 lines to col 2 line 12 col 10 lines 46-54 *;
 [Y]  - PRASHER V. P., "Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population", INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, (200406), vol. 19, no. 6, ISSN 0885-6230, pages 509 - 515, XP002532933 [Y] 1-3,5-9 * pages 510-511 *

DOI:   http://dx.doi.org/10.1002/gps.1077
 [Y]  - HOLMES C. ET AL., "The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease", NEUROLOGY, (20040727), vol. 63, no. 2, ISSN 0028-3878, pages 214 - 219, XP002532378 [Y] 1-3,5-9 * the whole document *
 [DY]  - GIACOBINI E., "Cholinesterase inhibitors stabilize Alzheimer disease.", NEUROCHEMICAL RESEARCH OCT 2000, (200010), vol. 25, no. 9-10, ISSN 0364-3190, pages 1185 - 1190, XP002532379 [DY] 1-3,5-9 * the whole document *

DOI:   http://dx.doi.org/10.1023/A:1007679709322
 [Y]  - TARIOT P.N. ET AL., "Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial.", JAMA (JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION), (20040121), vol. 291, no. 3, ISSN 0098-7484, pages 317 - 324, XP009075923 [Y] 1-3,5-9 * the whole document *

DOI:   http://dx.doi.org/10.1001/jama.291.3.317
International search[Y]US6242421  (BOWEN RICHARD LLOYD [US]);
 [Y]  - Japan parma stock market week to May 21, Market letter, Marketletter Publications Ltd. 28 May 2002, pg. 1
 [Y]  - RACCHI M. ET AL., "Acetylcholinesterase Inhibitors: Novel Activities of Old Molecules", PHARMACOLOGICAL RESEARCH, (20050518), vol. 50, pages 441 - 451, XP002998429

DOI:   http://dx.doi.org/10.1016/j.phrs.2003.12.027
 [Y]  - STRAETEMANS R., "Design and Analysis of Drug Combination Experiments", BIOMETRICAL JOURNAL, (2005), vol. 47, no. 3, pages 299 - 308, XP008076858

DOI:   http://dx.doi.org/10.1002/bimj.200410124
Examination   - FELDMAN HOWARD H ET AL, "Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis.", ALZHEIMER DISEASE AND ASSOCIATED DISORDERS 2005 JAN-MAR LNKD- PUBMED:15764869, (200501), vol. 19, no. 1, ISSN 0893-0341, pages 29 - 36
    - STERN R G ET AL, "A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.", THE AMERICAN JOURNAL OF PSYCHIATRY MAR 1994 LNKD- PUBMED:8109647, (199403), vol. 151, no. 3, ISSN 0002-953X, pages 390 - 396
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.